SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : analysts and calls -- ML
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: tom pope9/26/2005 12:25:50 PM
   of 238
 
CBST

Cubist Pharmaceuticals Inc (CBST, $19.55, C-1-9)
Reiterate Buy, Raising Target from $20 to $28. We are also raising our
Cubicin '06-'08 sales estimates. Higher dose of Cubicin may be used in
endocarditis and bacteremia patients than expected. The approvable letter
for dalbavancin may allow Cubicin to gain an incremental $10-40 MM in
sales in the next 1-3 years, depending on reason for the approvable.
Reiterate BUY. We are raising our Cubicin sales estimate to $199 MM
from $185 MM in '06, to $291 MM from $272 MM in '07, and to $385 MM
from $360 MM in '08. Our price target of $28 is based on a P/E of 32x
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News